ALX Oncology
ALXO
97 hedge funds and large institutions have $291M invested in ALX Oncology in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 15 closing their positions.
16,300% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $8K
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
1% more funds holding
Funds holding: 96 → 97 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.23% less ownership
Funds ownership: 90.56% → 88.33% (-2.2%)
53% less capital invested
Capital invested by funds: $622M → $291M (-$331M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$17M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.65M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.38M |
| 4 |
Millennium Management
New York
|
+$4.3M |
| 5 |
BlackRock
New York
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$10.9M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$3.84M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.82M |
ALXO Hedge Fund Activity: Q2 2022 in Review
97 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2022, worth a combined $291M — down 53% from $622M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALXO positions and 15 closed out — a net gain of 3 holders — while 36 added to existing stakes and 23 trimmed.
The largest buyer was OrbiMed, adding an estimated $17M. The largest seller was State Street, cutting an estimated $19.4M.
- 97 institutional investors held ALX Oncology (ALXO) as of Q2 2022, up from 96 in Q1 2022.
- Funds reported $291M of ALX Oncology stock for Q2 2022, down 53% quarter-over-quarter.
- 18 funds opened new ALX Oncology positions in Q2 2022 and 15 closed out, a net change of +3 holders.
- The largest ALX Oncology buyer in Q2 2022 was OrbiMed, an estimated $17M added.
- The largest ALX Oncology seller in Q2 2022 was State Street, an estimated $19.4M sold.
Based on aggregated 13F filings for Q2 2022.